Medication Reconciliation
Conditions
Keywords
Medication reconciliation, IT platform, Pharmacies
Brief summary
To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.
Detailed description
This trial will explore the alliance between a Cancer Institute and the community pharmacies to improve medication reconciliation in healthcare transitions, and will validate a new integrated IT platform. Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy participating to the trial, and to perform the pharmacological survey before every cycle of chemotherapy. This will be sent through the new IT platform to the electronic medical record of IRST, and the Oncologist will perform the reconciliation. Data about concomitant medications and possible interactions will be exensively analyzed.
Interventions
OTHERmedication reconciliation
medication reconciliation
Sponsors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult ≥18 years old * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Patients receiving an anticancer treatment * Clear understanding of the Italian language; written informed consent.
Exclusion criteria
\- None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| medication recognition and reconciliation maintenance | At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days) | number of reconciliations per patient |
Countries
Italy
Outcome results
None listed